WINTON GROUP Ltd Purchases 5,433 Shares of Insulet Corporation $PODD

WINTON GROUP Ltd boosted its position in shares of Insulet Corporation (NASDAQ:PODD) by 149.6% in the second quarter, HoldingsChannel reports. The fund owned 9,065 shares of the medical instruments supplier’s stock after purchasing an additional 5,433 shares during the quarter. WINTON GROUP Ltd’s holdings in Insulet were worth $1,380,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of PODD. California State Teachers Retirement System grew its holdings in Insulet by 13,901.9% in the second quarter. California State Teachers Retirement System now owns 14,562,256 shares of the medical instruments supplier’s stock worth $2,217,103,000 after purchasing an additional 14,458,254 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Insulet during the 2nd quarter valued at $1,018,582,000. Norges Bank purchased a new stake in shares of Insulet during the 4th quarter valued at $300,794,000. Arrowstreet Capital Limited Partnership boosted its position in shares of Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after purchasing an additional 1,011,369 shares in the last quarter. Finally, Man Group plc acquired a new stake in shares of Insulet in the 2nd quarter worth $78,746,000.

Insulet Price Performance

NASDAQ PODD opened at $131.96 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The stock’s fifty day moving average price is $152.36 and its 200 day moving average price is $173.92. Insulet Corporation has a 1 year low of $126.40 and a 1 year high of $354.88. The company has a market cap of $9.15 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 1.04 and a beta of 1.08.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. The company had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm’s revenue was up 23.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, equities research analysts forecast that Insulet Corporation will post 6.51 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Citigroup upped their target price on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Raymond James Financial reissued an “outperform” rating and issued a $180.00 price target on shares of Insulet in a report on Thursday, August 6th. Robert W. Baird set a $175.00 price target on Insulet in a research note on Thursday, August 6th. Weiss Ratings downgraded shares of Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, June 24th. Finally, Stifel Nicolaus cut their price objective on shares of Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $195.40.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.